Clinical Trial Update: Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating sorafenib in patients with unresectable stage III or stage IV melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Sorafenib (Nexavar) (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Stage III Melanoma, Stage IV Melanoma | Phase 2 | Status: COMPLETED